Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 118   

Articles published

JNJ 101.22 +0.86 (0.86%)
price chart
Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine ...
NEW BRUNSWICK, N.J., Oct. 22, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in ...
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson JNJ +0.86% (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
Johnson & Johnson (NYSE: JNJ) To Start Ebola Vaccine Trials
Vacinne, Johnson & Johnson, JNJ, Ebola, Virus, Bavarian Nordic This morning, Johnson & Johnson (NYSE: JNJ) announced plans to conduct Ebola vaccine trials on human volunteers starting early January 2015.
3 Drugs Critical to Johnson & Johnson's Future
Johnson & Johnson (NYSE: JNJ ) is one of the planet's largest companies with operations that stretch from consumer goods to medical devices, but it's drug business growth has led to J&J's climbing sales.
J&J sales top forecast, helped by drug for hep C
At the end of September, Johnson & Johnson announced plans to buy Alios BioPharma, a biotech company focused on developing existing therapies for viral diseases.
Gilead Retreats Following Johnson & Johnson Comments On HCV Drug
Why I'm in Johnson & Johnson for the long run  The Globe and Mail
Related articles »  
Johnson & Johnson to invest $200M in Ebola vaccine testing
Johnson & Johnson will begin safety testing in early January on a two-step vaccine that it hopes could protect people from a strain of the deadly Ebola virus.
What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock
Johnson & Johnson (NYSE: JNJ ) is one of the planet's biggest drugmakers. Its drugs are used for a variety of diseases, including cancer and autoimmune disorders, but it's J&J's sales of the hepatitis C drug Olysio that are most interesting to Gilead ...
Related articles »  
Johnson & Johnson Likely To Gain From Ebola Vaccine-Related News
Johnson & Johnson (JNJ) announced early Wednesday morning that it will begin running human trials for its Ebola vaccine in January 2015.
Johnson & Johnson Earnings Preview: Pharma Is Where The Party Is
This year has been eventful for Johnson & Johnson. The company completed the divestiture of Ortho-Clinical Diagnostics to Carlyle Group in Q3 2014 and got the approval for its new blockbuster drug Olysio in Europe in the second quarter.
Related articles »  
Why Johnson & Johnson (JNJ) Stock Is Up Today
NEW YORK (TheStreet) -- Johnson & Johnson (JNJ) shares are higher by 0.45% to $97.44 after the company reported third quarter net income of $4.7 billion, or $1.66 per diluted share, compared to $2.9 billion, or $1.04 per diluted share, for the same ...
Johnson & Johnson Earnings: Pharmaceutical Sales Again Lead the Way  Motley Fool
J&J's revenue up, but near flat sales growth in medical devices ... (blog)
Related articles »